Journal Updates
eMediNexus Coverage from: 
ABILITY-3 shows higher rates of maintenance remission with adalimumab
eMediNexus,  24 July 2018
remove_red_eye 659 Views
#Orthopedics #Pharmacist #Rheumatology

0 Read Comments                

In patients with active non-radiographic axial spondyloarthritis who achieved sustained remission with adalimumab, continued treatment with adalimumab was associated with significantly fewer patients flaring compared with treatment withdrawal. These findings from the ABILITY-3 trial were published online June 28, 2018 in The Lancet.
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!